Wedbush Reiterates Outperform on Tyra Biosciences, Maintains $53 Price Target
Wedbush analyst Robert Driscoll reiterates Tyra Biosciences (NASDAQ:TYRA) with a Outperform and maintains $53 price target.
Stocks · News reference
Why Is Tyra Biosciences Stock Sinking Wednesday?
Tyra Biosciences stock fell sharply as initial dabogratinib Phase 2 data showed a 57% complete response rate at 60 mg.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Apple To $370? Here Are 10 Top Analyst Forecasts For Thursday
Analysts cut targets for AAPL, CHWY, COO, TYRA and CNM; raised DLR, DPZ, SIG, while ratings stayed unchanged.
HC Wainwright & Co. Maintains Buy on Tyra Biosciences, Lowers Price Target to $30
HC Wainwright & Co. analyst Mitchell S. Kapoor maintains Tyra Biosciences (NASDAQ:TYRA) with a Buy and lowers the price target from $45 to $30.